Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Sep - Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.
Source: Bse
Wanbury Limited (WANBURY)
Small CapPharma stocks · Small cap · NSE
Wanbury Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result11 Aug, 08:59 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
54Neutralfull bear SMA stack · SMA20 -17.1% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 24
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
WANBURYD candles · FIT view-27.9%Latest close ₹186.06 on 2026-10-19
Bar
-3.5%
RSI
31
MACD hist
0.37
52W pos
12%
2026-10-19O ₹192.90H ₹194.95L ₹185.10C ₹186.06Vol 68,996 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
WANBURYNifty PharmaNifty 500
- WANBURY
- -45.3%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -39.7 pp
Chart stats
19 Oct 2026- From 52W high
- -48.2%
- 52W range position
- 12%
- ATR (14)
- 5.8%
- Volume vs 20D
- 0.21x
- Avg traded value
- ₹6.6 Cr
- 20D price channel
- ₹185 - ₹241.8
₹358.9
₹161.5 - ₹358.9
₹10.8
Latest completed session
20-session average
48.1% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED69
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +1.5% · PAT -76.0% YoY
Technical
Neutral54
Price trend and sector-relative-strength timing.
Valuation
Legacy model+74.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence59
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 0/100PAT -76% YoY · margin compression · Rev +1% YoY
Filed 11 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹165.6 Cr | +1.5% | +0.6% |
| EBITDA | ₹16.2 Cr | -33.6% | -45.6% |
| Operating margin | 9.8% | -518 bps | -833 bps |
| PAT | ₹3.2 Cr | -76.0% | -85.1% |
| PAT margin | 2.0% | -631 bps | -1123 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 11.20
- P/B
- 4.60
- EV/EBITDA
- 7.82
- Market Cap
- 666.00Cr
Profitability
- ROE
- 68.40%
- ROCE
- 30.70%
- ROA
- 10.81%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 11.00%
- EPS 5Y
- 48.00%
- Revenue 3Y
- 9.00%
- EPS 3Y
- 107.00%
Balance Sheet
- Debt/Equity
- 1.56
- Interest Coverage
- 3.30×
- Altman Z
- 3.36
- Book Value
- 41.30
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 9/5
- OCF
- 32.00 Cr
- EPS TTM
- 16.01
Shareholding
- Promoter Hold
- 43.01%
- Promoter Pledge
- 62.20%
- Momentum 52W
- 14%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 650+8.3% vs prev
Net Profit
₹ CrLatest: 66.0+112.9% vs prev
Return on Equity
%Latest: 45.5-13.4% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 31. Wait for confirmation.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~20.6% over last month) — short-term momentum negative.
- RSI(14) at 31 — sideways, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 48% off 52W high · 15% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
12
RS percentile
Stage 4 Downtrend
1M return
-16.5%
3M return
-45.3%
6M return
-31.0%
1Y return
-27.4%
RS 1D
-4
RS 20D
-22
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 27.9% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -2.5%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 76.76-2.28%
RS vs Nifty 50077
Valuation & peers
U-Score 69 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 69 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Growth at Value
Fundamental score breakdown
U band · UNDERVALUEDValuation20/30
Growth21/25
Quality18/20
Balance Sheet0/15
Cash Flow4/10
Piotroski
7/9 (+5)
Penalties
1
Raw sum
69
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
69/100 · legacy band UNDERVALUED
Positive drivers
- Piotroski is strong at 7/9.
- Fair-value margin of safety is positive at 74.2%.
- Quality contributes 18/20 to the score.
Main drags
- Promoter pledge is 62.2%.
- Balance sheet is weaker at 0/15; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
11.2
PB
4.6
EV/EBITDA
7.8
ROE
68.4%
ROCE
30.7%
FCF Yield
—
Debt/Equity
1.6
MoS
+74.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
69
Previous: 69
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+74.2%
Previous: +74.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
69
69
69
69
69
69
69
69
69
69
69
69
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹121.97
-52.5% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹720.45
+74.2% MoS
PEG
0.16
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
AMANTA
Small
Amanta Healthcare Limited
Pharmaceuticals
match 164
39
48.2
10.3%
+3%
WATCHLIST
ANUHPHR
Small
Anuh Pharma Limited
Pharmaceuticals
match 163
40
19.5
10.7%
+40%
WATCHLIST
ALBERTDAVD
Small
Albert David Limited
Pharmaceuticals
match 162
26
21.7
-0.4%
-23%
OVERVALUED
HALEOSLABS
Small
HALEOS LABS LIMITED
Pharmaceuticals
match 162
29
29.6
8.4%
-139%
OVERVALUED
BAFNAPH
Small
Bafna Pharmaceuticals Limited
Pharmaceuticals
match 161
27
—
-6.2%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Wanbury Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
59Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 25th percentile of the scored universe and 16th percentile within Pharma. Main check: promoter alignment is weak at 35/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
15 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
25th percentile
overall median 67 · Pharma: 16th pctile, median 70 · Small: 28th pctile, median 66
Evidence depth
Financial-only
15 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
35
weak · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
61
acceptable · leverage and solvency
Discipline
72
acceptable · capital discipline
Results
60
acceptable · quarterly consistency
Trust positives
- ▸9 years of positive FCF.
- ▸ROCE is 30.8%.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸Promoters have pledged 62.2% of holding.
- ▸Debt/equity is 1.54.
- ▸ROCE trend is -10.2%.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Wanbury Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 Aug - EDQM approved Rivaroxaban API; USFDA DMF clearances for Paraxetine HCI and Metformin HCI.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Annual Report 2025-26 And Notice Of The 38Th Annual General Meeting Of Wanbury Limited. 31 Aug - Wanbury issued FY26 annual report and AGM notice; seeks 5-year reappointment of Whole-time Director Mohan Kumar Rayana.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.